Cervical dysplasia is not cancer. It is a precancerous condition where cells on the surface of the cervix have begun to change and look abnormal under a microscope, but they have not gained the ability to invade deeper tissue or spread. The distinction matters because dysplasia is highly treatable, and in many cases, it resolves on its own without any treatment at all.
That said, untreated high-grade dysplasia can eventually become cervical cancer. The progression from an initial HPV infection through persistent dysplasia to invasive cancer takes an average of about 15 years, which is why routine screening catches the vast majority of cases long before they become dangerous.
What Makes Dysplasia Different From Cancer
The key difference comes down to what the abnormal cells are doing. In dysplasia, abnormal cells are confined to the thin layer of tissue lining the cervix (the epithelium). They look unusual, but they stay put. Cancer, by contrast, means cells have broken through that lining and begun growing into surrounding tissue, with the potential to spread elsewhere in the body.
Think of it as a spectrum. Normal cervical cells sit at one end, invasive cancer at the other, and dysplasia occupies the middle ground. Doctors grade dysplasia by how much of the cervical lining is affected:
- CIN 1 (mild): Abnormal cells involve about one-third of the epithelium’s thickness.
- CIN 2 (moderate): Abnormal cells extend through one-third to two-thirds.
- CIN 3 (severe): Abnormal cells affect more than two-thirds of the lining.
CIN 1 is considered low-grade and frequently clears up without intervention. CIN 2 and CIN 3 are high-grade, meaning the changes are more extensive and carry a greater risk of eventually progressing to cancer if left alone.
HPV Is the Primary Cause
Nearly all cervical dysplasia is triggered by persistent infection with high-risk strains of human papillomavirus, particularly HPV 16 and HPV 18. These two strains are responsible for the majority of high-grade lesions and cervical cancers. Other high-risk strains, including HPV 31, 33, and 45, also contribute but are less common.
Most HPV infections clear on their own within a year or two. Dysplasia develops when the virus persists and begins disrupting how cervical cells grow and divide. That’s why having an HPV infection doesn’t mean you’ll develop dysplasia, and having dysplasia doesn’t mean you’ll develop cancer. Each step requires the infection to linger and the cellular changes to deepen.
How Dysplasia Is Found
Cervical dysplasia causes no symptoms. You won’t feel it. It’s detected through screening, which is why regular Pap tests and HPV tests matter so much.
An abnormal Pap result doesn’t mean you have dysplasia or cancer. It means some of the cells collected from your cervix looked different from normal. Results fall into several categories. Minor changes, labeled ASC-US, often prompt an HPV test to check whether a high-risk strain is present. Low-grade changes (LSIL) typically indicate an HPV infection and may need follow-up testing. High-grade changes (HSIL) suggest moderate to severe abnormalities that need closer evaluation.
When results warrant a closer look, the next step is colposcopy. During this procedure, a doctor uses a magnifying instrument to examine the cervix after applying a vinegar solution that highlights abnormal areas. A small tissue sample (biopsy) is usually taken during the colposcopy. That biopsy is what provides an actual diagnosis of CIN 1, 2, or 3.
Many Cases Resolve on Their Own
One of the most reassuring aspects of cervical dysplasia is how often the body clears it without treatment. For CIN 1, observation is the preferred approach rather than treatment. Most low-grade changes resolve as the immune system clears the underlying HPV infection, and doctors typically recommend a repeat HPV test or co-test in one year to monitor progress.
CIN 2 also regresses more often than many people expect. In adult women, regression rates range from 70 to 80 percent over time, with an annual regression rate of 15 to 23 percent and up to 55 percent clearing within four to six years. In younger women, the numbers are even more encouraging. A prospective study of women with an average age of about 20 found that 38 percent cleared CIN 2 within one year, 63 percent by two years, and nearly 70 percent by three years. Adolescents and young women show regression rates above 90 percent.
For this reason, younger women with CIN 2 may be offered the option of close monitoring instead of immediate treatment, as long as they can commit to regular follow-up appointments.
When Treatment Is Needed
High-grade dysplasia that persists, particularly CIN 3, is typically treated to prevent progression. The two most common procedures are LEEP and cone biopsy (conization), both of which remove the abnormal tissue from the cervix.
LEEP is the more common option. It uses a thin, electrically heated wire loop to remove the affected tissue. It’s done in a clinic with local anesthesia to numb the cervix, takes only a few minutes, and you go home the same day. LEEP is particularly useful when abnormal tissue extends higher into the cervical canal where it can’t be seen directly.
Cone biopsy removes a larger, cone-shaped section of tissue. It’s done in a hospital or surgery center, typically under general anesthesia or an epidural, though you still go home the same day. Because it removes more tissue and can be more precise, it’s sometimes preferred when the doctor needs a larger sample to confirm whether cancer is present or when LEEP isn’t sufficient.
Both procedures serve a dual purpose: they treat the dysplasia by removing it and provide a tissue sample for further examination to confirm the diagnosis and rule out anything more serious.
What Happens Without Treatment
Studying what happens when CIN 3 is left untreated is, for obvious ethical reasons, nearly impossible. The most well-documented data comes from a controversial New Zealand study that followed women with untreated CIN 3 over roughly 30 years. While most cases of CIN 3 don’t progress, the risk of invasive cancer climbs significantly the longer high-grade changes go unaddressed. Rapid-onset cancers do occur in some cases, even if the average timeline from HPV infection to cancer spans about 15 years.
This is precisely why screening programs exist. Cervical dysplasia is far more common than cervical cancer itself. Population-based data has shown dysplasia rates of roughly 195 per 100,000 women annually, compared to cervical cancer rates between about 8 and 15 per 100,000. The gap between those numbers reflects how effectively screening and treatment intercept the process before cancer develops.
HPV Vaccination Cuts the Risk Dramatically
The HPV vaccine is the most effective tool for preventing cervical dysplasia in the first place. The current nine-strain vaccine prevents approximately 90 percent of cervical cancers and 70 to 85 percent of high-grade cervical disease. In clinical trials, vaccination reduced the incidence of disease related to HPV 16 and 18 by over 95 percent compared to placebo.
The vaccine works best when given before exposure to HPV, which is why it’s recommended in early adolescence. But even among women who have already been treated for dysplasia, prior vaccination significantly reduces the chance of developing new abnormal lesions afterward. In one study, women who had received the nine-strain vaccine before undergoing cervical excision surgery had a 95 percent lower rate of subsequent HPV 16/18-related disease compared to unvaccinated women.